Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 01 June, 2010 and appeared in  MedicationBlood Glucose ControlIssue 524

Tracking Blood Sugar with Nano-Tattoos

Chemical engineers are working on carbon nanotubes that could be injected under the skin to reveal blood glucose levels.... 

Advertisement

People with diabetes must prick their fingers several times a day to test their blood sugar level. Though the pain is minor, the chore interferes with daily life.

"They never really escape it," says Paul Barone, a postdoctoral researcher in MIT's Department of Chemical Engineering. Barone and professor Michael Strano are working on a new type of blood glucose monitor that could not only eliminate the need for finger pricks but also offer more accurate readings.

"Diabetes is an enormous problem, global in scope, and despite decades of engineering advances, our ability to accurately measure glucose in the human body still remains quite primitive," says Strano, the Charles and Hilda Roddey Associate Professor of Chemical Engineering. "It is a life-and-death issue for a growing number of people."

Strano and Barone's sensing system consists of a "tattoo" of nanoparticles designed to detect glucose, injected below the skin. A device similar to a wristwatch would be worn over the tattoo, displaying the patient's glucose levels.

A 2008 study in the New England Journal of Medicine showed that continuous monitoring helped adult Type 1 diabetes patients who were at least 25 years old better control their blood glucose levels. However, existing wearable devices are not as accurate as the finger-prick test and have to be recalibrated once or twice a day -- a process that still involves pricking the finger.

Most existing continuous glucose sensors work via an injection of an enzyme called glucose oxidase, which breaks down glucose. An electrode placed on the skin interacts with a by-product of that reaction, hydrogen peroxide, allowing glucose levels to be indirectly measured. However, none of those sensors have been approved for use longer than seven days at a time.

The technology behind the MIT sensor, described in a December 2009 issue of ACS Nano, is fundamentally different from existing sensors, says Strano. The sensor is based on carbon nanotubes wrapped in a polymer that is sensitive to glucose concentrations. When this sensor encounters glucose, the nanotubes fluoresce, which can be detected by shining near-infrared light on them. Measuring the amount of fluorescence reveals the concentration of glucose.

The researchers plan to create an "ink" of these nanoparticles suspended in a saline solution that could be injected under the skin like a tattoo. The "tattoo" would last for a specified length of time, probably six months, before needing to be refreshed.

To get glucose readings, the patient would wear a monitor that shines near-infrared light on the tattoo and detects the resulting fluorescence. One advantage of this type of sensor is that, unlike some fluorescent molecules, carbon nanotubes aren't destroyed by light exposure. "You can shine the light as long as you want, and the intensity won't change," says Barone. Because of this, the sensor can give continuous readings.

Barone and Strano are now working to improve the accuracy of their sensor. Any glucose monitor must pass a test known as the Clarke Error Grid, the gold standard for glucose-sensor accuracy. The test, which compares sensor results to results from a lab-based glucose meter, needs to be very stringent, since mistakes in glucose detection can be fatal.

They are still years away from human trials, says Barone, but they may soon start trials in animals. Those tests will be key to determining the value of this approach, says Bruce Buckingham, a professor of pediatric endocrinology at the Stanford School of Medicine and an author of the NEJM study. "You don't know how good it will be until you put it in someone and see how strong the signal is," he says.

MIT Press Release, May 28

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 01 June, 2010 and appeared in  MedicationBlood Glucose ControlIssue 524

Past five issues: Diabetes Clinical Mastery Series Issue 85 | Issue 626 | Special Edition - Getting Patients on Track | Diabetes Clinical Mastery Series Issue 84 | Issue 625 |

 
Diabetes In Control Advertisers
 
 
Cast Your Vote
Now that once-weekly GLP-1 is available, which product are you recommending for your type 2 patients?

Navigate Diabetes In Control
Announcement:
Search Articles On Diabetes In Control